Complete cytogenetic remission in a patient with FIP1L1-PDGFRA fusion negative chronic eosinophilic leukemia associated with atypical thrombotic events

  • A. Zabernigg
  • M. Erdel
  • R. Schranzhofer
  • K. Berek
  • K. Gattringer
Case report

Summary

We present a rare case of a patient with chronic eosinophilic leukemia, who did not develope the well known organ involvements of the heart, lungs, the skin or nervous system, but who suffered form atypical thrombotic complications including a life threatening sinovenous thrombosis. His disease showed a rapid response to a very low dose of imatinib an the complete remission of a complex cytogenetic abnormality.

Keywords

Hypereosinophilic syndrome Chronich eosinophilic leukemia Thrombosis Imatinib 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hellmich B, Holl-Ulrich K Gross W. Hypereosinophiles Syndrom: Aktueller Stand der Diagnostik und Therapie. Dtsch Med Wochenschr, 132: 1892–1896, 2007PubMedCrossRefGoogle Scholar
  2. Roufossue F, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Diseases, 2: 37, 2007 (DOI: 10.1186/1750-1172-2-37)CrossRefGoogle Scholar
  3. Roufosse F, Cogan A, Goldman M. Recent advances in the pathogenesis and management of hypereosinopholic syndromes. Allergy, 59: 673–689, 2004PubMedCrossRefGoogle Scholar
  4. Cools J, DeAngelo D, Gotlib J, et al. A tyrosin kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 348: 1201–1214, 2003PubMedCrossRefGoogle Scholar
  5. Cross NCP, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia, 16: 1207–1212, 2002PubMedCrossRefGoogle Scholar
  6. Narayan S, Ezughah F, Standen G, et al. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol, 148: 817–820, 2003PubMedCrossRefGoogle Scholar
  7. Schulman H, Hertzog L, Zirkin H, Hertzanu Y. Cerebral sinovenous thrombosis in the idiopathic hypereosinophilic syndrome in childhood. Pediatr Radiol, 29: 595–597, 1999PubMedCrossRefGoogle Scholar
  8. Cortes J, Ault P, Koller Ch, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 101: 4714–4716, 2003PubMedCrossRefGoogle Scholar
  9. Onitilo A, Kio E, Singh A, Lazarchick J. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. Leuk Lymphoma, 46(11): 1667–1670, 2005PubMedCrossRefGoogle Scholar
  10. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Haematol, 58(2): 137–141, 1998CrossRefGoogle Scholar
  11. Rothenberg M, Gleich G, Roufosse F, Rossenwasser L, Weller P. Steroid sparing effect of anti-IL5 antibody (mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood, 108: 373, 2006Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • A. Zabernigg
    • 1
  • M. Erdel
    • 2
  • R. Schranzhofer
    • 1
  • K. Berek
    • 3
  • K. Gattringer
    • 1
  1. 1.Department of Internal Medicine and OncologyGeneral Hospital KufsteinKufsteinAustria
  2. 2.Department of Medical Genetics, Molecular and Clinical PharmacologyUniversity InnsbruckInnsbruckAustria
  3. 3.Department of NeurologyGeneral Hospital KufsteinKufsteinAustria

Personalised recommendations